

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-2 (canceled)

3. (withdrawn) The composition of Claim 2 wherein the first appetite suppressant is a Mc4r agonist, and pharmaceutically acceptable salts and esters thereof, and the second appetite suppressant is selected from the group consisting of

- (1) a MCH1R antagonist; and
- (2) a MCH2R agonist/antagonist;

and pharmaceutically acceptable salts and esters thereof.

4. (withdrawn) The composition of Claim 2 wherein the first appetite suppressant is a CB-1 antagonist/inverse agonist, and pharmaceutically acceptable salts and esters thereof, and the second appetite suppressant is selected from the group consisting of

- (1) a NPY1 antagonist;
- (2) a NPY2 agonist;
- (3) a NPY4 agonist;
- (4) a MCH1R antagonist;
- (5) a MCH2R agonist/antagonist; and
- (6) a Mc4r agonist;

and pharmaceutically acceptable salts and esters thereof.

Claims 5-48 (canceled)

49. (new) A composition comprising two appetite suppressants, wherein each appetite suppressant is selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) phentermine;

and pharmaceutically acceptable salts and esters thereof;

provided that the appetite suppressants have different biological mechanisms of action.

50. (new) The composition of Claim 49 further comprising a pharmaceutically acceptable carrier.

51. (new) A method of treating a subject having a disorder associated with excessive food intake comprising administration of a therapeutically effective amount of two appetite suppressants selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) phentermine;

and pharmaceutically acceptable salts and esters thereof;
provided that the appetite suppressants have different biological mechanisms of action.

52. (new) The method according to Claim 51 wherein the disorder associated with excessive food intake is obesity.

53. (new) The method according to Claim 51 wherein the disorder associated with excessive food intake is an obesity-related disorder.

54. (new) The method according to Claim 53 wherein the obesity-related disorder is diabetes.

55. (new) A composition comprising two appetite suppressants, wherein each appetite suppressant is selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) a NPY2 agonist;

and pharmaceutically acceptable salts and esters thereof;
provided that the appetite suppressants have different biological mechanisms of action.

56. (new) The composition of Claim 55 further comprising a pharmaceutically acceptable carrier.

57. (new) A method of treating a subject having a disorder associated with excessive food intake comprising administration of a therapeutically effective amount of two appetite suppressants selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and

(2) a NPY2 agonist;
and pharmaceutically acceptable salts and esters thereof;
provided that the appetite suppressants have different biological mechanisms of action.

58. (new) The method according to Claim 57 wherein the disorder associated with excessive food intake is obesity.

59. (new) The method according to Claim 57 wherein the disorder associated with excessive food intake is an obesity-related disorder.

60. (new) The method according to Claim 59 wherein the obesity-related disorder is diabetes.

61. (new) A composition comprising two appetite suppressants, wherein each appetite suppressant is selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) a Mc4r agonist;

and pharmaceutically acceptable salts and esters thereof;
provided that the appetite suppressants have different biological mechanisms of action.

62. (new) The composition of Claim 61 further comprising a pharmaceutically acceptable carrier.

63. (new) A method of treating a subject having a disorder associated with excessive food intake comprising administration of a therapeutically effective amount of two appetite suppressants selected from the group consisting of

- (1) a CB-1 antagonist/inverse agonist; and
- (2) a Mc4r agonist;

and pharmaceutically acceptable salts and esters thereof;
provided that the appetite suppressants have different biological mechanisms of action.

64. (new) The method according to Claim 63 wherein the disorder associated with excessive food intake is obesity.

65. (new) The method according to Claim 63 wherein the disorder associated with excessive food intake is an obesity-related disorder.

66. (new) The method according to Claim 65 wherein the obesity-related disorder is diabetes.